10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

NCT01081509 ·Status: COMPLETED

Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase

NCT03259711 ·Status: COMPLETED

Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

NCT06776458 ·Status: RECRUITING

Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment

NCT01144572 ·Status: COMPLETED

Letrozole in Preventing Breast Cancer in Postmenopausal Women

NCT00090857 ·Status: COMPLETED ·Phase: PHASE2

Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

NCT06781762 ·Status: RECRUITING

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

NCT01275859 ·Status: COMPLETED ·Phase: PHASE2

Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

NCT00681928 ·Status: COMPLETED

Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

NCT01069211 ·Status: UNKNOWN

Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia

NCT04541212 ·Status: ACTIVE_NOT_RECRUITING

Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients

NCT02812277 ·Status: UNKNOWN

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620 ·Status: COMPLETED ·Phase: PHASE3

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698 ·Status: COMPLETED

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

NCT00638391 ·Status: COMPLETED

Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment

NCT01596530 ·Status: TERMINATED ·Phase: PHASE1

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

NCT00078832 ·Status: COMPLETED ·Phase: PHASE3

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

NCT03111615 ·Status: UNKNOWN ·Phase: PHASE4

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05439499 ·Status: UNKNOWN ·Phase: PHASE3

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110 ·Status: COMPLETED ·Phase: PHASE2

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215 ·Status: TERMINATED ·Phase: PHASE2

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836 ·Status: COMPLETED

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

NCT00719966 ·Status: COMPLETED

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

NCT01298362 ·Status: COMPLETED

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

NCT00238316 ·Status: COMPLETED ·Phase: PHASE2

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3